Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS to make 100% of claims data public

This article was originally published in The Gray Sheet

Executive Summary

Researchers will soon get a gift from Medicare - they'll be able to order selections of data from up to 100% of claims. Steve Phurrough, CMS Coverage & Analysis Group director, told an audience at the Transcatheter Cardiovascular Therapeutics meeting Oct. 25 in Washington, D.C., that the database will include all Medicare claims data, beginning with 2005, including inpatient, outpatient, nursing home and durable medical equipment data. "You will be able as a researcher to say to us, 'I want to see all your data on MI, or kidney stones,' whatever it is that you want, and it will be 100% of our claims," he said. At present, researchers can only request a selection of about 5% of the data. Phurrough hopes that with expanded availability, mandated by the Medicare Modernization Act, CMS will see more clinical data that can be applied directly to the Medicare population...

You may also be interested in...



EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel